-+ 0.00%
-+ 0.00%
-+ 0.00%

Actinium Pharmaceuticals Presents New Preclinical Data For ATNM-400 Antibody Radioconjugate At 32nd Annual Prostate Cancer Foundation Scientific Retreat In Carlsbad, California

Benzinga·10/24/2025 12:31:58
Listen to the news

Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a pioneer in the development of differentiated targeted radiotherapies, today highlighted new preclinical data for ATNM-400, its novel, first-in-class antibody radioconjugate armed with the potent alpha-emitter Actinium-225 (Ac-225) at the 32nd Annual Prostate Cancer Foundation (PCF) Scientific Retreat being held October 23 – 25, 2025 in Carlsbad, CA. 

ATNM-400, which targets a non-PSMA antigen associated with prostate cancer progression and treatment resistance, demonstrated superior tumor control and improved overall survival compared with the active agents in key standard-of-care therapies including enzalutamide (the active agent in Xtandi®, Astellas/Pfizer) and 177Lu-PSMA-617 (the active agent in Pluvicto®, Novartis), as well as 225Ac-PSMA-617 across multiple preclinical prostate cancer models.